Technology ID
TAB-4872
Advancements in HIV-1 Treatment with Broadly Neutralizing Monoclonal Antibodies N6 and VRC07-523LS
E-Numbers
E-049-2019-0
Lead Inventor
Kwong, Peter
Lead IC
NIAID
Co-Inventors
Mascola, John
Chuang, Gwo-Yu
Zhang, Baoshan
Asokan, Mangaiarkarasi
Doria-Rose, Nicole
McKee, Krisha
Pegu, Amarendra ("Amar")
ICs
NIAID
Applications
Vaccines
Therapeutics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Clinical Phase I
Research Products
Antibodies
The Vaccine Research Center has engineered two monoclonal antibodies, N6 and VRC07-523LS, as new contenders in the fight against HIV-1. These antibodies are designed to target the virus more effectively by removing certain glycans and modifying amino acids to enhance their neutralizing capability and reduce the risk of autoimmunity. The technology holds promise for improved HIV-1 treatments and may offer broader protection due to its potential coverage of various viral variants. This advancement signifies a strategic move towards more effective clinical solutions for HIV-1 prevention and treatment, with a focus on antibody-based therapies.
Commercial Applications
The N6 and VRC07-523LS antibodies are promising tools for HIV-1 prophylaxis and active treatment. Their broad neutralization profiles suggest potential for inclusion in vaccine formulations. These antibodies could adapt to combat diverse HIV-1 strains, enhancing treatment efficacy. Their development represents a significant step forward in the personalized approach to HIV-1 management.
Competitive Advantages
N6 and VRC07-523LS monoclonal antibodies offer a competitive advantage in the HIV-1 treatment landscape due to their enhanced neutralizing efficacy and reduced autoreactivity. Their tailored design increases product uniformity and anticipates broad effectiveness across HIV-1 variants, positioning them as promising candidates for future therapeutic developments.
Licensing Contact: